Next generation of boron neutron capture therapy (BNCT) agents for cancer treatment.
Coghi P, Li J, Hosmane NS, Zhu Y.
Med Res Rev. 2023 Sep;43(5):1809-1830. doi: 10.1002/med.21964. Epub 2023 Apr 27.
Boron neutron capture therapy (BNCT): a unique role in radiotherapy with a view to entering the accelerator-based BNCT era.
Suzuki M.
Int J Clin Oncol. 2020 Jan;25(1):43-50. doi: 10.1007/s10147-019-01480-4. Epub 2019 Jun 5.
A PD-L1 siRNA-Loaded Boron Nanoparticle for Targeted Cancer Radiotherapy and Immunotherapy.
Deng S, Hu L, Chen G, Ye J, Xiao Z, Guan T, Guo S, Xia W, Cheng D, Wan X, Cheng K, Ou C.
Adv Mater. 2025 Apr;37(13):e2419418. doi: 10.1002/adma.202419418. Epub 2025 Feb 16.
Boron Vehiculating Nanosystems for Neutron Capture Therapy in Cancer Treatment.
Ailuno G, Balboni A, Caviglioli G, Lai F, Barbieri F, Dellacasagrande I, Florio T, Baldassari S.
Cells. 2022 Dec 13;11(24):4029. doi: 10.3390/cells11244029.
Boron delivery agents for neutron capture therapy of cancer.
Barth RF, Mi P, Yang W.
Cancer Commun (Lond). 2018 Jun 19;38(1):35. doi: 10.1186/s40880-018-0299-7.
Boron neutron capture enhanced fast neutron radiotherapy for malignant gliomas and other tumors.
Buchholz TA, Laramore GE, Stelzer KJ, Risler R, Wootton P, Griffin TW.
J Neurooncol. 1997 May;33(1-2):171-8. doi: 10.1023/a:1005798004420.
[Boron neutron capture a a new radiotherapy model].
Hideghéty K, Sauerwwein W, Rassuw J, Sack H.
Orv Hetil. 1998 Mar 22;139(12):675-9.
Boron neutron capture therapy for glioblastoma.
Yamamoto T, Nakai K, Matsumura A.
Cancer Lett. 2008 Apr 18;262(2):143-52. doi: 10.1016/j.canlet.2008.01.021. Epub 2008 Mar 4.
Boron nanodrugs for boron neutron capture therapy.
Wan J, Lv L, Chang Y, Li J, Xing G, Chen K.
Appl Radiat Isot. 2025 Nov;225:112044. doi: 10.1016/j.apradiso.2025.112044. Epub 2025 Jul 17.
Development of a Gadolinium-Boron-Conjugated Albumin for MRI-Guided Neutron Capture Therapy.
Okada S, Nishimura K, Ainaya Q, Shiraishi K, Anufriev SA, Sivaev IB, Sakurai Y, Suzuki M, Yokoyama M, Nakamura H.
Mol Pharm. 2023 Dec 4;20(12):6311-6318. doi: 10.1021/acs.molpharmaceut.3c00726. Epub 2023 Nov 1.
